Bagcchi S. Who’s global tuberculosis report 2022. Lancet Microb. 2023;4(1):e20.

Article  Google Scholar 

Alvarez AH, Flores-Valdez MA. Can immunization with bacillus calmette-guerin be improved for prevention or therapy and elimination of chronic mycobacterium tuberculosis infection? Expert Rev Vaccines. 2019;18(12):1219–27.

Article  CAS  PubMed  Google Scholar 

Lovey A, Verma S, Kaipilyawar V, et al. Early alveolar macrophage response and il-1r-dependent t cell priming determine transmissibility of mycobacterium tuberculosis strains. Nat Commun. 2022;13(1):884.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paik S, Kim KT, Kim IS, et al. Mycobacterial acyl carrier protein suppresses tfeb activation and upregulates mir-155 to inhibit host defense. Front Immunol. 2022;13:946929.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Su H, Zhu S, Zhu L, et al. Recombinant lipoprotein rv1016c derived from mycobacterium tuberculosis is a tlr-2 ligand that induces macrophages apoptosis and inhibits mhc ii antigen processing. Front Cell Infect Microbiol. 2016;6:147.

Article  PubMed  PubMed Central  Google Scholar 

Hwang SA, Ali Y, Fedotova E, et al. Morphoproteomics identifies the foamy alveolar macrophage as an m2 phenotype with pd-l1 expression in the early lesion of post-primary tuberculosis: Implications for host immune surveillance and therapy. Ann Clin Lab Sci. 2020;50(4):429–38.

CAS  PubMed  Google Scholar 

Wang L, Otkur W, Wang A, et al. Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis via downregulating the mtor pathway. Front Pharmacol. 2022;13:906043.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei M, Jiang Y, Sun R, et al. Self-assembly of a linear-dendritic polymer containing cisplatin and norcantharidin into raspberry-like multimicelle clusters for the efficient chemotherapy of liver cancer. ACS Appl Mater Interfaces. 2023;15(11):14664–77.

Zhai BT, Sun J, Shi YJ, et al. Review targeted drug delivery systems for norcantharidin in cancer therapy. J Nanobiotechnology. 2022;20(1):509.

Article  PubMed  PubMed Central  Google Scholar 

Xiao S, Wang Y, Ma W, et al. Intraperitoneal administration of thermosensitive hydrogel co-loaded with norcantharidin nanoparticles and oxaliplatin inhibits malignant ascites of hepatocellular carcinoma. Drug Delivery. 2022;29(1):2713–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou J, Ren Y, Tan L, et al. Norcantharidin: Research advances in pharmaceutical activities and derivatives in recent years. Biomed Pharmacother. 2020;131:110755.

Article  CAS  PubMed  Google Scholar 

Zhao Q, Qian Y, Li R, et al. Norcantharidin facilitates lps-mediated immune responses by up-regulation of akt/nf-kappab signaling in macrophages. PLoS ONE. 2012;7(9):e44956.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu XH, Blazsek I, Comisso M, et al. Effects of norcantharidin, a protein phosphatase type-2a inhibitor, on the growth of normal and malignant haemopoietic cells. Eur J Cancer. 1995;31A(6):953–63.

Article  CAS  PubMed  Google Scholar 

Zheng J, Qian ZM, Sun YX, et al. Downregulation of hepcidin by norcantharidin in macrophage. Nat Prod Res. 2023;38(4):1–6.

Article  Google Scholar 

Zheng J, Wang JJ, Ma HM, et al. Norcantharidin down-regulates iron contents in the liver and spleen of lipopolysaccharide-treated mice. Redox Rep. 2022;27(1):119–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han Z, Li B, Wang J, et al. Norcantharidin inhibits sk-n-sh neuroblastoma cell growth by induction of autophagy and apoptosis [J]. Technol Cancer Res Treat. 2017;16(1):33–44.

Article  CAS  PubMed  Google Scholar 

Du LJ, Feng YX, He ZX, et al. Norcantharidin ameliorates the development of murine lupus via inhibiting the generation of il-17 producing cells. Acta Pharmacol Sin. 2022;43(6):1521–33.

Article  CAS  PubMed  Google Scholar 

Qiu P, Wang S, Liu M, et al. Norcantharidin inhibits cell growth by suppressing the expression and phosphorylation of both egfr and c-met in human colon cancer cells. BMC Cancer. 2017;17(1):55.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Z, Sun B, Lu J, et al. Norcantharidin inhibits the malignant progression of cervical cancer by inducing endoplasmic reticulum stress. Mol Med Rep. 2024;29(5):71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li XP, Jing W, Sun JJ, et al. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking vegf-a,-c,-d/vegfr-2,-3 “multi-points priming” mechanisms in vitro and in vivo. BMC Cancer. 2015;15:527.

Article  PubMed  PubMed Central  Google Scholar 

Gao Y, Li W, Liu R, et al. Norcantharidin inhibits il-6-induced epithelial-mesenchymal transition via the jak2/stat3/twist signaling pathway in hepatocellular carcinoma cells. Oncol Rep. 2017;38(2):1224–32.

Article  CAS  PubMed  Google Scholar 

Chen YC, Chang SC, Wu MH, et al. Norcantharidin reduced cyclins and cytokines production in human peripheral blood mononuclear cells. Life Sci. 2009;84(7–8):218–26.

Article  CAS  PubMed  Google Scholar 

Li B, Wang W, Zhao L, et al. Photothermal therapy of tuberculosis using targeting pre-activated macrophage membrane-coated nanoparticles. Nat Nanotechnol. 2024;19(6):834–45.

Article  CAS  PubMed  Google Scholar 

Gupta A, Thirunavukkarasu S, Rangel-Moreno J, et al. Phospholipase c epsilon-1 (plce1) mediates macrophage activation and protection against tuberculosis. Infect Immun. 2024;92(4):e0049523.

Article  PubMed  Google Scholar 

Park JY, Kim HD, Abekura F, et al. A novel mycobacterium tuberculosis antigen, mtb48 enhances inflammatory response in lps-induced raw 264.7 macrophage immune cells. Mol Immunol. 2024;166:50–7.

Article  CAS  PubMed  Google Scholar 

Mwebaza I, Shaw R, Li Q, et al. Impact of mycobacterium tuberculosis glycolipids on the cd4+ t cell-macrophage immunological synapse. J Immunol. 2023;211(9):1385–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ge B. Mycobacterium tuberculosis suppresses host DNA repair to boost its intracellular survival. Cell Host Microbe. 2023;2023(31):1–17.

Google Scholar 

Bedard M, van der Niet S, Bernard EM, et al. A terpene nucleoside from m. Tuberculosis induces lysosomal lipid storage in foamy macrophages. J Clin Invest. 2023;133(6):e161944.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maglione PJ, Xu J, Casadevall A, et al. Fc gamma receptors regulate immune activation and susceptibility during mycobacterium tuberculosis infection [J]. J Immunol. 2008;180(5):3329–38.

Article  CAS  PubMed  Google Scholar 

Cox DJ, Coleman AM, Gogan KM, et al. Inhibiting histone deacetylases in human macrophages promotes glycolysis, il-1beta, and t helper cell responses to mycobacterium tuberculosis. Front Immunol. 2020;11:1609.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang S, Zhou X, Ou M, et al. Berbamine promotes macrophage autophagy to clear mycobacterium tuberculosis by regulating the ros/ca(2+) axis. mBio. 2023;14(4):e0027223.

Article  PubMed  Google Scholar 

Gupta PK, Jahagirdar P, Tripathi D, et al. Macrophage targeted polymeric curcumin nanoparticles limit intracellular survival of mycobacterium tuberculosis through induction of autophagy and augment anti-tb activity of isoniazid in raw 264.7 macrophages. Front Immunol. 2023;14:1233630.